BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.67.

A number of analysts have issued reports on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, JMP Securities lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 7th.

Insider Transactions at BioCryst Pharmaceuticals

In related news, Director Machelle Sanders sold 4,689 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the transaction, the director now owns 27,742 shares in the company, valued at approximately $166,452. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Machelle Sanders sold 4,689 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the transaction, the director now owns 27,742 shares in the company, valued at approximately $166,452. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nancy J. Hutson bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The shares were bought at an average price of $6.38 per share, with a total value of $31,900.00. Following the transaction, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 103,601 shares of company stock valued at $596,338. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC raised its position in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares during the last quarter. Tidal Investments LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $282,000. Redwood Investment Management LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $621,000. Jacobs Levy Equity Management Inc. raised its position in BioCryst Pharmaceuticals by 62.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 156,119 shares of the biotechnology company’s stock valued at $793,000 after purchasing an additional 59,722 shares during the last quarter. Finally, Kynam Capital Management LP raised its position in BioCryst Pharmaceuticals by 41.9% in the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after purchasing an additional 1,927,491 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 1.6 %

BCRX opened at $7.15 on Friday. The firm has a market capitalization of $1.48 billion, a P/E ratio of -6.68 and a beta of 1.88. The stock’s 50 day moving average price is $6.24 and its two-hundred day moving average price is $5.67. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $7.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the business earned ($0.28) EPS. As a group, analysts anticipate that BioCryst Pharmaceuticals will post -0.66 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.